New 'Cold' ablation device aims to zap heart rhythm problems without heat

NCT ID NCT07018596

Recruiting now Disease control Sponsor: Pulse Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new device called the CellFX nsPFA catheter, which uses short electrical pulses instead of heat to treat paroxysmal atrial fibrillation (a type of irregular heartbeat). The goal is to see if it is safe and effective at restoring normal rhythm in 215 adults who have not responded well to medication. The procedure targets the heart's pulmonary veins to block faulty signals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CellFX nsPFA Cardiac Catheter System (device using nanosecond pulsed field ablation)
What this could lead to: If successful, this could offer a safer, more precise way to treat atrial fibrillation without heat, potentially reducing complications and improving recovery.
What could go wrong: This is an early-stage device trial with 215 participants, so results may not apply to everyone. Risks include stroke, heart damage, or other serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (PAROXYSMAL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation paroxysmal atrial fibrillation ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (PAROXYSMAL) CARDIAC ABLATION CARDIAC ARRHYTHMIA

Contacts and locations

Locations

Na Homolce Hospital
RECRUITING

Prague, Roentgenova, 37/2, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.